Compare Inovio Pharmaceuticals Inc (INO) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nomura Holdings Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M), while Nomura Holdings Inc trades at $9.82 (market cap $28.46B). The key difference: Nomura Holdings Inc is far larger — about 362.3× Inovio Pharmaceuticals Inc's market cap, and Nomura Holdings Inc pays a 3.31% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NMR | |
|---|---|---|
Market Cap | $78.55M | $28.46B |
Sector | Health | Financials |
52-Week High | $2.87 | $10.04 |
52-Week Low | $0.66 | $6.73 |
Enterprise Value | $49.56M | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Nomura Holdings (NMR) trades at $9.925, up 1.07% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $1.66 trillion and net income of $340.74 billion, yielding a net margin of 20.4%. Recent earnings show a mix of beats and misses, with Q2 2026 EPS beating expectations. Analyst consensus leans toward Hold, with 66.67% of coverage recommending Hold and 33.33% Buy.
The outlook for NMR is supported by robust profitability and valuation metrics like a P/E of 11.59, suggesting potential undervaluation. However, risks include inconsistent cash flow from operations, rising debt-to-asset ratios, and macroeconomic sensitivity. Investors should weigh solid fundamentals against cash flow volatility and debt trends for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
